Perfluorohexyloctane |
|
Catalog No.GC72644
|
Perfluorohexyloctane is a semifluorinated alkane ophthalmic preparation used for the treatment of dry eye disease.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 133331-77-8
Sample solution is provided at 25 µL, 10mM.
Perfluorohexyloctane is a semifluorinated alkane ophthalmic preparation used for the treatment of dry eye disease. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film to inhibit water evaporation and stabilize the tear film. Perfluorohexyloctane supplements lipids, improves meibomian gland secretion, and reduces ocular surface inflammation. Perfluorohexyloctane can be used in studies on evaporative dry eye, meibomian gland dysfunction-associated dry eye, and ocular surface inflammation repair[1-4].
In vitro, exposure of human HepaRG hepatocytes to 0.44%-12.32% (v/v) perfluorohexyloctane for 24 hours altered amino acid, fatty acid, and lipid metabolism. Intracellular lipid levels decreased at low perfluorohexyloctane concentrations and increased at high perfluorohexyloctane concentrations[5].
References:[1] Zhuang-Yan A, Syed YY. Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease. Drugs. 2024 Apr;84(4):441-448.
[2] Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2023;130(5):516-524.
[3] Malchiodi-Albedi F, Matteucci A, Formisano G, et al. Perfluorohexyloctane(F6H8) induces structural modifications and increases apoptosis in rat primary retinal cultures. J Biomed Mater Res Part B Appl Biomater. 2003;65B:133-136
[4] Le VNH, Hos D, Hou Y, et al. VEGF TrapR1R2 suspended in the semifluorinated alkane F6H8 inhibits inflammatory corneal hem- and lymphangiogenesis. Trans Vis Sci Tech. 2020;9(11):15.
[5] Alijagic A, Chaker J, Barbosa JMG, et al. Metabolic effects and biotransformation of perfluorohexyloctane in human hepatocytes. Environ Int. 2026;208:110112.
| Cell experiment [1]: | |
|
Cell lines |
HepaRG cells (human hepatic cell line) |
|
Preparation Method |
HepaRG cells were maintained in basal hepatic cell medium supplemented with HepaRG Growth Medium Supplement with antibiotics at 37°C, 5% CO2, differentiated for 14 days, seeded at 106 cells/well, and exposed to 0.44%-12.32% v/v Perfluorohexyloctane for 24 hours. After exposure, cell pellets and supernatant were collected for metabolomic analysis by UHPLC-QTOFMS. |
|
Reaction Conditions |
0.44%-12.32% v/v; 24h |
|
Applications |
Perfluorohexyloctane altered amino acid, fatty acid, and lipid metabolism. Perfluorohexyloctane downregulated several lipids at low concentration and upregulated multiple lipids at high concentration. Perfluorohexyloctane induced the formation of a biotransformation product, perfluorohexyloctanoic acid. |
| References: [1] Alijagic A, Chaker J, Barbosa JMG, et al. Metabolic effects and biotransformation of perfluorohexyloctane in human hepatocytes. Environ Int. 2026;208:110112. | |
| Cas No. | 133331-77-8 | SDF | |
| Formula | C14H17F13 | M.Wt | 432.26 |
| Solubility | DMSO : 100 mg/mL (231.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3134 mL | 11.5671 mL | 23.1342 mL |
| 5 mM | 462.7 μL | 2.3134 mL | 4.6268 mL |
| 10 mM | 231.3 μL | 1.1567 mL | 2.3134 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A Liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















